Review
Immunology
Bernd Heinrich, Firouzeh Korangy
Summary: Innate lymphoid cells (ILCs) are a heterogeneous population of the innate immune system that play a crucial role in maintaining immune homeostasis. They exhibit high plasticity, allowing them to quickly respond to changes in their microenvironment. ILCs can transdifferentiate into different subsets in the tumor microenvironment, influencing the immune response and tumor therapy. This review summarizes the functional and plastic heterogeneity of ILCs in homeostasis and disease, with a focus on tumor-driven plasticity and the impact of ILC-induced inflammation on the tumor microenvironment and anti-tumor immunity.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Oncology
Rongying Tan, Manhua Nie, Wang Long
Summary: B cells play a critical role in adaptive immune responses through antigen presentation and antibody production, but their function in tumor immunity varies among different tumor types. Antigen presentation of B cells is mainly anti-tumoral, while the role of antibody production is controversial. Immunosuppressive regulatory B cells negatively affect anti-tumor immunity through the secretion of anti-inflammatory cytokines.
FRONTIERS IN ONCOLOGY
(2022)
Review
Immunology
Alexander S. Martin, Michael Molloy, Andrey Ugolkov, Reinhard W. von Roemeling, Randolph J. Noelle, Lionel D. Lewis, Melissa Johnson, Laszlo Radvanyi, Robert E. Martell
Summary: V-domain Ig suppressor of T-cell activation (VISTA) is a novel immunotherapy target for solid tumors, playing key roles in maintaining T cell quiescence and regulating myeloid cell populations. Understanding the biology of VISTA and its interactions with tumor and immune cells is crucial for anti-VISTA therapy. We provide a general framework to describe patterns of VISTA expression in correlation with other immune biomarkers across solid tumors, facilitating the investigation of effective tumor microenvironments for VISTA-targeted treatment.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Engineering, Environmental
Gaizhen Kuang, Qingfei Zhang, Yunru Yu, Xiaoya Ding, Weijian Sun, Xian Shen, Yuanjin Zhao
Summary: Immunotherapy is important for treating malignant tumors. A sponge-nanofiber Janus scaffold has been developed for tumor postoperative immuno-chemotherapy, containing lyophilization-inactivated cancer cells, immune adjuvant imiquimod, and 5-fluorouracil (5-FU). The scaffold exhibits excellent anti-recurrence and anti-metastasis efficiency in a mouse breast tumor model, making it a promising option for combination therapy after tumor surgery.
CHEMICAL ENGINEERING JOURNAL
(2023)
Review
Immunology
Elena V. Abakushina, Liubov I. Popova, Andrey A. Zamyatnin, Jens Werner, Nikolay V. Mikhailovsky, Alexandr V. Bazhin
Summary: In the past decade, significant progress has been made in adoptive cell therapy, with dendritic cell vaccines and NK cells being potential cell preparations for cancer treatment. While NK cell immunotherapy shows high efficacy and promise against many types of cancer, there are still challenges to be overcome, such as infiltration limitations and low cytotoxic activity in solid tumors.
Article
Oncology
Yangyang Zhang, Lingxiu Zeng, Meng Wang, Zhenwei Yang, Hailin Zhang, Liping Gao, Ranran Zhang, Jialong Liu, Wenqing Shan, Ying Chang, Lan Liu, Qiu Zhao, Yong Li, Jing Liu
Summary: The study found that RIG-I plays an important role in the immunotherapy of colon cancer by maintaining the stability of PD-L1 to promote immune evasion. Silencing RIG-I increases the sensitivity of tumor cells to T cell killing and slows down the growth of colon tumors. High expression of RIG-I promotes tumor progression and enhances the sensitivity to PD-1 therapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Qiushi Tang, Shuo Yang, Guangpeng He, Hongyu Zheng, Sheng Zhang, Jiaxing Liu, Shibo Wei, Qing Fan, Xueqiang Peng, Xinyu Li, Dewei Zhang, Liang Yang, Hangyu Li
Summary: Tumor-derived exosomes (TDEs) play a critical role in regulating the immune microenvironment of tumors and have the ability to suppress immune responses, thus impacting the effectiveness of cancer therapy. By delivering suppressive factors to immune cells, TDEs directly or indirectly influence immune cell function and antitumor activities. TDE-based therapy is emerging as a promising strategy for inhibiting tumor progression and enhancing antitumor immunity.
Article
Oncology
A. J. Robert McGray, Jessie L. Chiello, Takemasa Tsuji, Mark Long, Kathryn Maraszek, Nicole Gaulin, Spencer R. Rosario, Suzanne M. Hess, Scott Abrams, Danuta Kozbor, Kunle Odunsi, Emese Zsiros
Summary: The therapeutic efficacy of cancer immunotherapies in ovarian cancer is limited. Researchers have developed T cells that secrete a bispecific T-cell engager targeting the folate receptor alpha commonly overexpressed in OC. These T cells efficiently lyse tumor cells and induce antitumor immunity. Preconditioning of T cells with cytokines improves therapeutic efficacy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Chemistry, Multidisciplinary
Jingjing Ding, Guihong Lu, Weidong Nie, Li-Li Huang, Yahui Zhang, Wenlin Fan, Guanghao Wu, Houli Liu, Hai-Yan Xie
Summary: An engineered self-activatable photo-EV for synergistic trimodal anticancer therapy has been reported, which utilizes M1 EVs to simultaneously load multiple drugs, achieving synergism of immunotherapy, photodynamic therapy, and chemotherapy with great promise in fighting cancers.
ADVANCED MATERIALS
(2021)
Review
Oncology
Junyi An, Xiaohua Hu, Feng Liu
Summary: Cancer stem cells (CSCs) possess immune privilege properties to evade immune system attack. Gastrointestinal CSCs (GCSCs) are involved in tumor initiation, progression, metastasis, and recurrence, with high resistance to conventional therapies. Targeting GCSCs through immunotherapy is a promising strategy.
FRONTIERS IN ONCOLOGY
(2023)
Review
Immunology
Laurent Schmied, Petter Hoglund, Stephan Meinke
Summary: The interactions between platelets and cancer cells play a significant role in supporting tumor metastasis by promoting vascular evasion and establishing solid tumor metastasis, as well as contributing to an immunosuppressive tumor microenvironment. Platelets are a major source of TGF-beta, which is crucial in immunosuppression. While the interactions between platelets and solid tumors are well-studied, their physiological relevance in hematological malignancies requires further research.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Oncology
Xiuyun Xuan, Chunxia Tian, Mengjie Zhao, Yanhong Sun, Changzheng Huang
Summary: The tumor microenvironment plays a crucial role in cancer progression and therapeutic resistance, with MSCs being a distinct type of cells linked to tumor development. MSCs can both promote and inhibit cancer cell proliferation and metastasis, as well as contribute to therapeutic resistance.
CANCER CELL INTERNATIONAL
(2021)
Review
Oncology
Emily A. Henderson, Slawomir Lukomski, Brian A. Boone
Summary: Pancreatic cancer has a low survival rate and is resistant to current treatments. Bacterial mediated cancer therapies have gained recognition for their potential in enhancing immune response and mitigating adverse effects. This review focuses on bacterial mechanisms, challenges, and opportunities for the management of pancreatic ductal adenocarcinoma.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Anna Morena D'Alise, Guido Leoni, Maria De Lucia, Francesca Langone, Linda Nocchi, Fabio Giovanni Tucci, Elisa Micarelli, Gabriella Cotugno, Fulvia Troise, Irene Garzia, Rosa Vitale, Veronica Bignone, Elena Di Matteo, Rosa Bartolomeo, Deborah H. Charych, Armin Lahm, Jonathan Zalevsky, Alfredo Nicosia, Elisa Scarselli
Summary: The addition of a third component to the combination of anti-PD-1 and vaccine led to complete eradication of large tumors and reduction of tumor-infiltrating regulatory T cells. These findings support the concept that integrating three steps of the cancer immunity cycle can achieve higher cure rates by expanding neoantigen-specific T cells, reversing exhausted T cell phenotype, and reducing intratumoral Tregs.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Dieke J. van Rees, Panagiota Bouti, Bart Klein, Paul J. H. Verkuijlen, Michel van Houdt, Karin Schornagel, Anton T. J. Tool, David Venet, Christos Sotiriou, Sarra El-Abed, Miguel Izquierdo, Sebastien Guillaume, Cristina Saura, Serena Di Cosimo, Jens Huober, Rebecca Roylance, Sung-Bae Kim, Taco W. Kuijpers, Robin van Bruggen, Timo van den Berg, Hanke L. Matlung
Summary: The study demonstrates that tumor cells can escape neutrophil-mediated cytotoxicity through calcium-dependent cell membrane repair. Knocking down EXOC7 or EXOC4 renders tumor cells vulnerable to neutrophil-mediated cytotoxicity, while neutrophil trogocytosis remains unaffected. mRNA levels of exocyst components in trastuzumab-treated patients were inversely correlated to treatment response.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Review
Oncology
Lorenzo Galluzzi, Ilio Vitale, Sarah Warren, Sandy Adjemian, Patrizia Agostinis, Aitziber Buque Martinez, Timothy A. Chan, George Coukos, Sandra Demaria, Eric Deutsch, Dobrin Draganov, Richard L. Edelson, Silvia C. Formenti, Jitka Fucikova, Lucia Gabriele, Udo S. Gaipl, Sofia R. Gameiro, Abhishek D. Garg, Encouse Golden, Jian Han, Kevin J. Harrington, Akseli Hemminki, James W. Hodge, Dewan Md Sakib Hossain, Tim Illidge, Michael Karin, Howard L. Kaufman, Oliver Kepp, Guido Kroemer, Juan Jose Lasarte, Sherene Loi, Michael T. Lotze, Gwenola Manic, Taha Merghoub, Alan A. Melcher, Karen L. Mossman, Felipe Prosper, Oystein Rekdal, Maria Rescigno, Chiara Riganti, Antonella Sistigu, Mark J. Smyth, Radek Spisek, John Stagg, Bryan E. Strauss, Daolin Tang, Kazuki Tatsuno, Stefaan W. van Gool, Peter Vandenabeele, Takahiro Yamazaki, Dmitriy Zamarin, Laurence Zitvogel, Alessandra Cesano, Francesco M. Marincola
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2020)
Article
Cell Biology
Alessandra Rossi, Valeria Lucarini, Iole Macchia, Paola Sestili, Carla Buccione, Simona Donati, Maria Ciccolella, Antonella Sistigu, Maria Teresa D'Urso, Anna Maria Pacca, Enrico Cardarelli, Fabrizio Mattei, Enrico Proietti, Giovanna Schiavoni, Laura Bracci
Review
Immunology
Antonella Sistigu, Martina Musella, Claudia Galassi, Ilio Vitale, Ruggero De Maria
FRONTIERS IN IMMUNOLOGY
(2020)
Article
Biochemistry & Molecular Biology
Gwenola Manic, Martina Musella, Francesca Corradi, Antonella Sistigu, Sara Vitale, Sara Soliman Abdel Rehim, Luca Mattiello, Eva Malacaria, Claudia Galassi, Michele Signore, Matteo Pallocca, Stefano Scalera, Frauke Goeman, Francesca De Nicola, Andrea Guarracino, Rosa Pennisi, Fabrizio Antonangeli, Francesca Sperati, Marta Baiocchi, Mauro Biffoni, Maurizio Fanciulli, Marcello Maugeri-Sacca, Annapaola Franchitto, Pietro Pichierri, Ruggero De Maria, Ilio Vitale
Summary: This passage discusses the crucial role of cancer stem cells in colorectal cancer and the research findings on PARP1 and MRE11/RAD51, providing new insights for tumor treatment.
CELL DEATH AND DIFFERENTIATION
(2021)
Article
Multidisciplinary Sciences
Adele De Ninno, Francesca Romana Bertani, Annamaria Gerardino, Giovanna Schiavoni, Martina Musella, Claudia Galassi, Fabrizio Mattei, Antonella Sistigu, Luca Businaro
Summary: Cutting-edge tools for complex disease models need to provide physiologically and pathologically relevant insights to understand invisible processes. Advanced cell assays mimicking in vivo scenery are crucial for visualizing and measuring tumor-host interactions. These methods can simulate the complexity of tumor microenvironments and hold great potential for personalized oncology.
JOVE-JOURNAL OF VISUALIZED EXPERIMENTS
(2021)
Article
Oncology
Luca Mattiello, Sara Soliman Abdel Rehim, Martina Musella, Antonella Sistigu, Andrea Guarracino, Sara Vitale, Francesca Corradi, Claudia Galassi, Francesca Sperati, Gwenola Manic, Ruggero De Maria, Ilio Vitale
Summary: The targeting of RAD51 or MRE11 improves the sensitivity of primary CRC-SCs to CHK1/2 inhibitors by inducing replication stress, abrogating cell cycle checkpoints, and causing mitotic defects, leading to mitotic catastrophe and apoptosis. This approach may offer a promising strategy for eradicating cancer stem cells in colorectal cancer patients.
Review
Cell Biology
Claudia Galassi, Martina Musella, Nicoletta Manduca, Ester Maccafeo, Antonella Sistigu
Summary: Cancer stem cells (CSCs) have the ability to evade immune surveillance and are located at the apex of tumor aggressiveness and therapy resistance. Understanding the immunobiology of CSCs is crucial for identifying new therapeutic opportunities in cancer treatment.
Review
Biology
Paola Trono, Annalisa Tocci, Martina Musella, Antonella Sistigu, Paola Nistico
Summary: The actin cytoskeleton plays a crucial role in maintaining cell shape and responding to stimuli, but can also be exploited by pathogens, leading to cellular dysfunction. Chronic inflammation and cancer can induce a viral mimicry alarm status through modulation of the cytoskeleton, promoting tumor progression. Understanding the molecular mechanisms of cytoskeleton-mediated viral mimicry is critical for developing effective anti-cancer strategies in the rapidly advancing field of immuno-oncology.
Review
Biology
Martina Musella, Claudia Galassi, Nicoletta Manduca, Antonella Sistigu
Summary: Type I Interferons play crucial immune stimulatory functions in cancer settings, but depending on dose and timing, they may also foster cancer progression and immune evasion. Dysregulations of Type I IFN signaling cascade in the tumor microenvironment are critical determinants of therapeutic resistance to various anticancer treatments.
Article
Immunology
Martina Musella, Andrea Guarracino, Nicoletta Manduca, Claudia Galassi, Eliana Ruggiero, Alessia Potenza, Ester Maccafeo, Gwenola Manic, Luca Mattiello, Sara Soliman Abdel Rehim, Michele Signore, Marco Pietrosanto, Manuela Helmer-Citterich, Matteo Pallocca, Maurizio Fanciulli, Tiziana Bruno, Francesca De Nicola, Giacomo Corleone, Anna Di Benedetto, Cristiana Ercolani, Edoardo Pescarmona, Laura Pizzuti, Francesco Guidi, Francesca Sperati, Sara Vitale, Daniele Macchia, Massimo Spada, Giovanna Schiavoni, Fabrizio Mattei, Adele De Ninno, Luca Businaro, Valeria Lucarini, Laura Bracci, Eleonora Arico, Giovanna Ziccheddu, Francesco Facchiano, Stefania Rossi, Massimo Sanchez, Alessandra Boe, Mauro Biffoni, Ruggero De Maria, Ilio Vitale, Antonella Sistigu
Summary: The study demonstrates that type I interferons can promote the formation of cancer stem cells by upregulating the chromatin remodeling factor KDM1B. Inhibition of KDM1B could potentially prevent stem cell expansion and increase the long-term benefit of therapy.
Letter
Biochemistry & Molecular Biology
Martina Musella, Nicoletta Manduca, Ester Maccafeo, Antonella Sistigu
Summary: Immunogenic- and immune-therapies have become popular for cancer treatment, but resistance is a common challenge. Combining these therapies with epigenetic therapy has shown potential in improving clinical outcomes by targeting immune inhibitory signals. This article focuses on epigenetic dysregulations in cancer, particularly innate immune signaling and Type I interferons, and discusses efforts to translate this knowledge into effective treatment regimens.
Review
Oncology
Ilio Vitale, Takahiro Yamazaki, Erik Wennerberg, Baldur Sveinbjornsson, Oystein Rekdal, Sandra Demaria, Lorenzo Galluzzi
Summary: The high heterogeneity among malignant cells poses a significant obstacle to the success of cancer therapy, calling for the development of approaches that can operate despite such intratumoral heterogeneity. Oncolytic peptides, with their ability to induce immunogenic cell death and robust anticancer immune responses independently of intratumoral heterogeneity, show promise as therapeutic tools.
Correction
Oncology
Lorenzo Galluzzi, Ilio Vitale, Sarah Warren, Sandy Adjemian, Patrizia Agostinis, Aitziber Buque Martinez, Timothy A. Chan, George Coukos, Sandra Demaria, Eric Deutsch, Dobrin Draganov, Richard L. Edelson, Silvia C. Formenti, Jitka Fucikova, Lucia Gabriele, Udo S. Gaipl, Sofia R. Gameiro, Abhishek D. Garg, Encouse Golden, Jian Han, Kevin J. Harrington, Akseli Hemminki, James W. Hodge, Dewan Md Sakib Hossain, Tim Illidge, Michael Karin, Howard L. Kaufman, Oliver Kepp, Guido Kroemer, Juan Jose Lasarte, Sherene Loi, Michael T. Lotze, Gwenola Manic, Taha Merghoub, Alan A. Melcher, Karen L. Mossman, Felipe Prosper, Oystein Rekdal, Maria Rescigno, Chiara Riganti, Antonella Sistigu, Mark J. Smyth, Radek Spisek, John Stagg, Bryan E. Strauss, Daolin Tang, Kazuki Tatsuno, Stefaan W. van Gool, Peter Vandenabeele, Takahiro Yamazaki, Dmitriy Zamarin, Laurence Zitvogel, Alessandra Cesano, Francesco M. Marincola
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2020)
